Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like Covid-19, diabetes, liver disease and other illnesses affecting more and more of the population, pharmaceutical companies are racing to find cures – further advancing medicine and driving pharma stock prices higher.

Big Pharma corporations like AstraZeneca, Merck & Co., Pfizer, and Johnson & Johnson are leading the charge against the novel coronavirus, competing with smaller biotech names — such as Moderna and Novavax. The race to find a Covid-19 vaccine has sent both pharma and biotech stocks to the moon.

Novartis Flu Vaccine Ban: Who Wins?

By James Brumley, InvestorPlace Feature Writer
Two of Novartis' flu vaccines have been banned in seven countries, but the market's reaction to the move may be a bit overdone. Here's why.

Bristol-Myers, Eli Lilly Miss Q3 Forecasts, Shares Slide

By Christopher Freeburn, InvestorPlace Writer
Bristol-Myers Squibb and Eli Lilly reported third-quarter earnings that missed Wall Street estimates as generic competition slammed drug sales.

Should I Buy Abbott Labs? 3 Pros, 3 Cons

By Dan Burrows, InvestorPlace Feature Writer
Success in a drug regimen meant to treat hepatitis C is buoying shares of Abbott Laboratories, but has the easy money in ABT shares already been made?

Avoid Pharma Options — Except for This One

By Ken Trester
Most of the big pharmaceuticals are either in a downtrend or have reached a plateau. Lilly is the outlier worth trading calls on.

FDA Pulls Approval for a Generic Antidepressant

By Christopher Freeburn, InvestorPlace Writer
A generic version of antidepressant Wellbutrin has lost FDA approval after tests showed it less effective than the brand name drug at a certain dosage.

Woman’s $180 Stock Buy Balloons to $7M

By Nate Wooley, InvestorPlace Writer
Sometimes buy and hold REALLY does pay off. The late Grace Groner's purchase of three Abbott Labs shares in 1935 worked out well.

A Healthy Portfolio Is Heavy in Health Care

By Jeff Reeves
Investors would be foolish to ignore the massive demographic shift and growth potential that is boosting health care stocks right now.

Who Has the Best Pharma Pipeline?

By James Brumley, InvestorPlace Feature Writer
A look through Big Pharma's drug pipelines shows a lot of promise across several companies, but one firm stands out as having big-time revenue growth potential.

Believe In This M&A Mastermind

By James Brumley, InvestorPlace Feature Writer
Including its Medicis deal, Valeant Pharmaceuticals has made 27 acquisitions in the past four-plus years -- and it's showing no signs of capsizing.

Bet on Biotech With ViroPharma

By Jon Markman, Editor, Trader's Advantage and CounterPoint Options
Biotech stocks are speculative picks. But if you're willing to take a risk, ViroPharma is the way to go.

Gilead Poised to Go From Good to Great?

By James Brumley, InvestorPlace Feature Writer
Gilead faces a pivotal FDA decision on its HIV "quad" pill Monday. Even if it's not much better than what's available, approval would be good news for investors.

Banking on Buyouts in Biotech: Is It Smart?

By Jeff Reeves
Unless you really understand medicine, it's a very risky game. The chances of a little company scoring big and getting bought out are usually slim.

Cracked Wood in Market Resistance Zone Spells Trouble

By Richard Band
Markets may be getting ahead of themselves at this point, and savvy investors may want to revisit some portfolio names that have run up, including these pharmas

Israel: Beyond the Risk, Opportunities Beckon

By Alyssa Oursler, InvestorPlace Contributor
When you think of Israel, you probably think of conflict. But it has a strong economy and growing companies if you're willing to be a bit daring.

Ariad Pharmaceuticals: Steady Wins This Race

By John Kmiecik, InvestorPlace Contributor
A covered call strategy is ideal for a stock that's rising gradually. But it's also wise for traders to have strategies at hand no matter what happens next.

Is Arena Pharmaceuticals Any More Attractive Now That the Dust Is Settling?

By James Brumley, InvestorPlace Feature Writer
Now that the Belviq approval-fueled craze has waned, investors can take a clearer look at Arena's numbers. They might be pleasantly surprised.

How to Pick the Best High-Yield Stocks in Big Pharma

By Jeff Reeves
Big Pharma is a great place to find yield, and health care is a sure-fire long-term bet. But rather than shake a stick at this sector, go ahead ... be picky.

CVS Caremark Tops Q2 Profit, Misses on Revenue

By Christopher Freeburn, InvestorPlace Writer
CVS Caremark posted increased second-quarter earnings that topped Wall Street forecasts, but missed on revenue, and raised its earnings outlook for the year.

Pharma’s Q2 Earnings Lesson: The Big Picture Looks Good

By James Brumley, InvestorPlace Feature Writer
The promising signs coming out of pharma this quarter doesn't mean you can just pick a stock out of a hat -- but it does mean a few are worth picking.
Load More